A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of 10 Mg Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of 10 Mg Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer
This study is being done to evaluate the safety and efficacy of atrasentan in men with metastatic hormone-refractory prostate cancer.
Inclusion Criteria:
Exclusion Criteria:
Chapel Hill, North Carolina 27599-7235, United States
Daws Park, South Australia 5041, Australia
North York, Ontario M6A 3B5, Canada
Homburg / SAAR, 66421, Germany
Petermaritzburg, 3201, South Africa
Galdakao-Vizcaya, 48960, Spain